Developing a Mouse Model of Chronic Pseudomonas aeruginosa Skin Wound Infection
JoVE Encyclopedia of Experiments
Microbiology
0 views • 2:24 min • February 2nd, 2026
Loading...
Overview
This study investigates the formation of a chronic infection in a mouse model using a luminescent strain of Pseudomonas aeruginosa. The methodology involves creating skin wounds and monitoring bacterial growth within a provisional matrix.
Key Study Components
Area of Science
- Microbiology
- Infection Biology
- Animal Models
Background
- Pseudomonas aeruginosa is a common pathogen associated with chronic infections.
- Understanding biofilm formation is crucial for developing treatment strategies.
- Mouse models are widely used to study wound healing and infection.
- The role of the provisional matrix in bacterial attachment is significant.
Purpose of Study
- To examine the conditions that promote biofilm formation in wounds.
- To assess the impact of a transparent film dressing on infection dynamics.
- To monitor bacterial luminescence as a measure of infection severity.
Methods Used
- Creation of full-thickness excisional skin wounds in anesthetized mice.
- Application of a transparent film dressing to isolate the wounds.
- Injection of a luminescent strain of Pseudomonas aeruginosa into the wounds.
- Monitoring of luminescence to track bacterial infection over time.
Main Results
- Successful establishment of a chronic infection model in mice.
- Observation of biofilm formation within the provisional matrix.
- Correlation between luminescence and bacterial load in the wounds.
- Demonstration of the film dressing's role in infection dynamics.
Conclusions
- The study provides insights into the mechanisms of chronic infection development.
- Findings highlight the importance of the provisional matrix in supporting bacterial growth.
- This model can be used for future research on infection prevention strategies.
Frequently Asked Questions
What is the significance of using a luminescent strain of Pseudomonas aeruginosa?
The luminescent strain allows for real-time monitoring of bacterial infection through luminescence measurement.
How does the transparent film dressing affect the infection?
The dressing isolates the wound, creating a favorable environment for biofilm formation and bacterial growth.
What are the implications of this study for chronic wound management?
Understanding biofilm dynamics can inform strategies to prevent and treat chronic infections in wounds.
What methods were used to assess bacterial infection?
Luminescence was recorded to monitor the severity of the bacterial infection over time.
Why is the mouse model used in this research?
Mouse models are effective for studying wound healing and the dynamics of infections in a controlled environment.
Executive Industry Relevance
This model enables mechanistic de-risking of anti-infective candidates by establishing a reproducible chronic Pseudomonas aeruginosa wound infection system. Bioluminescence quantification provides predictive confidence for target validation and lead identification in antimicrobial development. The approach supports translational biomarker alignment and preclinical model continuity for wound-healing programs.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Interrogates therapeutic hypotheses on biofilm formation and bacterial persistence in wound environments.
- Operational Value: Enables functional target validation through quantifiable bacterial burden measurements over time.
- Predictive Value: Supports portfolio triage by correlating luminescence signals with infection chronicity and treatment response.
Screening & Assay Development
- Assay Readiness: Prepares validated biological systems for downstream antimicrobial compound evaluation.
- Quantitative Outputs: Delivers reproducible luminescence measurements enabling standardized assay conditions.
- Screening Scalability: Facilitates reliable compound screening through controlled infection establishment and monitoring.
Translational & Preclinical Research
- Disease Relevance: Models chronic wound infection pathophysiology relevant to human clinical scenarios.
- Translational Continuity: Bridges discovery findings to preclinical validation through consistent infection metrics.
- Risk-Adjusted Decisions: Informs advancement criteria based on biofilm formation and bacterial load thresholds.
Pipeline & Workflow Integration
The model integrates into antimicrobial discovery workflows from target validation through lead optimization to preclinical efficacy testing.
- Discovery Biology: Supports hypothesis testing on virulence factors and host-pathogen interactions in wound niches.
- Screening: Delivers assay readiness via standardized infection establishment and bioluminescence readouts.
- Analytics: Provides quantitative bacterial burden measurements enabling dose-response and time-course analyses.
- Translational Research: Connects mechanism-based findings to preclinical continuity through infection progression tracking.
- Enterprise Reuse: Establishes a reusable chronic infection platform for multiple antimicrobial programs.
Operational & Enterprise Impact
- Scientific Value: Reduces mechanistic ambiguity in anti-infective target validation through biofilm-relevant infection modeling.
- Operational Value: Ensures standardization and reproducibility via defined wound creation and bacterial inoculation procedures.
- Strategic Value: Improves go/no-go decisions by predicting clinical chronic infection outcomes from preclinical data.
- Portfolio Impact: Enables risk-adjusted prioritization of antimicrobial candidates based on biofilm eradication efficacy.
Implementation Considerations
- Requires expertise in murine wound modeling and bioluminescence imaging techniques.
- Dependent on instrumentation for luminescence detection and transparent film dressing maintenance.
- Necessitates cross-team standardization of wound size, bacterial dose, and inoculation timing.
- Involves adaptation considerations for different Pseudomonas strains or wound types.
- Limited by the need for specialized animal facility capabilities and biosafety containment.
Biopharma FAQs
Why does null hypothesis testing matter for target validation in this model?
Null hypothesis testing determines whether observed luminescence changes reflect true treatment effects rather than random variation in bacterial burden. This statistical approach validates target engagement by confirming significant differences between treated and control infection groups. It supports confident go/no-go decisions in antimicrobial target validation programs.
How does independent variable isolation fit the antimicrobial discovery pipeline?
Isolating the independent variable (e.g., compound concentration) ensures that changes in luminescence are attributable to the test agent alone. This control enables clear interpretation of structure-activity relationships during lead optimization. It maintains assay integrity across screening campaigns by minimizing confounding variables in infection models.
What quantitative dependent variable measurements enable in this wound infection model?
Luminescence measurements provide a quantitative dependent variable for tracking bacterial burden over time with high sensitivity. These measurements enable precise calculation of bacterial load reduction and infection progression rates. The quantitative output supports robust statistical analysis and cross-study comparison in antimicrobial efficacy assessments.
Why do replication requirements matter for cross-functional collaboration in this model?
Replication requirements ensure that infection establishment and luminescence readings are consistent across different operators and laboratories. This consistency enables reliable data sharing between discovery, preclinical, and translational teams. Standardized replication supports regulatory-aligned documentation and technology transfer across global R&D sites.
What statistical analysis capabilities are required before implementing this model?
Implementation requires capabilities for longitudinal data analysis to track luminescence changes over multiple time points. Teams need statistical tools for comparing bacterial burden between treatment groups using appropriate variance models. These capabilities enable calculation of effect sizes, confidence intervals, and power analysis for study design optimization.
06:55
Protocol to Create Chronic Wounds in Diabetic Mice
Related Videos
0 Views
08:30
A Novel High-Throughput Ex Vivo Ovine Skin Wound Model for Testing Emerging Antibiotics
Related Videos
0 Views
07:16
Swine Model of Biofilm Infection and Invisible Wounds
Related Videos
0 Views
04:00
A Murine Skin Wound Infection Model to Study the Immune Response against a Bacterial Pathogen
Related Videos
0 Views
15:43
Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
Related Videos
0 Views
07:24
Pseudomonas aeruginosa Induced Lung Injury Model
Related Videos
0 Views
09:15
Come to the Light Side: In Vivo Monitoring of Pseudomonas aeruginosa Biofilm Infections in Chronic Wounds in a Diabetic Hairless Murine Model
Related Videos
0 Views
09:15
A Mouse Model to Assess Innate Immune Response to Staphylococcus aureus Infection
Related Videos
0 Views
06:56
A Delayed Inoculation Model of Chronic Pseudomonas aeruginosa Wound Infection
Related Videos
0 Views
06:04
Modeling Persistent Pseudomonas aeruginosa Infection in Wounded Zebrafish Larvae
Related Videos
0 Views
Last updated: 15 August 2026